Active vaccine

Version vom 23. Juni 2020, 12:59 Uhr

32105090 2020. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic

• mrna-1273, moderna

32183941 2020. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2
32298218 2020. Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19
32209231 2020. Computers and viral diseases Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus
32219057 ä. The SARS-CoV-2 Vaccine Pipeline: an Overview
32148172 2020. Timely development of vaccines against SARS-CoV-2
32269766 2020. In silico identification of vaccine targets for 2019-nCoV
32265848 2020. Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
32300370 2020. Can an effective SARS-CoV-2 vaccine be developed for the older population?
32259480 ä. SARS-CoV-2 Vaccines: Status Report
32291382 2020. Coronavirus Vaccines: Light at the End of the Tunnel
32352026 2020. Epitope based vaccine prediction for SARS-COV-2 by deploying immuno-informatics approach
32295479 2020. Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study
32372051 ä. Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2
32335161 ä. In the search of potential epitopes for Wuhan seafood market pneumonia virus using high order nullomers
32232474 ä. Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure

• Oxford vaccine failed in monkeys

32348489 ä. COVID-19: Is Everything Appropriate to Create an Effective Vaccine?
32328406 ä. Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains
32022276 2020. Immunoinformatics?aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019?nCoV
32249203 ä. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development

• Nature: The COVID-19 vaccine development landscape

32353328 2020. What policy makers need to know about COVID-19 protective immunity
32171450 2020. Identification of potential cross-protective epitope between a new type of coronavirus (2019-nCoV) and severe acute respiratory syndrome virus
32265331 2020. Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection
32355330 ä. Inactivated vaccine for SARS-CoV-2
32289117 2020. Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus
32346092 ä. Cancer therapy tool informs COVID-19 vaccines
32194995 2020. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
32229574 2020. News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine
32347054 2020. Strategies for vaccine development of COVID-19
32304139 ä. Progress and Concept for COVID?19 Vaccine Development
32295153 2020. What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?
32235387 2020. Progress and Prospects on Vaccine Development against SARS-CoV-2
32106567 2020. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies
32249063 ä. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
32362491 ä. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: (Trends in Immunology 41, 355?359; 2020)
32340998 2020. Covid-19: What do we know so far about a vaccine?
32366511 2020. Developing a vaccine for covid-19
32379348 2020. 3CL hydrolase-based multiepitope peptide vaccine against SARS-CoV-2 using immunoinformatics
32320059 2020. Potential of live pathogen vaccines for defeating the COVID-19 pandemic: history and mechanism
32285942 2020. Defining Protective Epitopes for COVID-19 Vaccination Models
32375002 ä. Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery
32366816 2020. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
32376359 ä. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2
32355243 2020. Scores of coronavirus vaccines are in competition - how will scientists choose the best?
32227757 2020. Developing Covid-19 Vaccines at Pandemic Speed
32234130 2020. Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)
32245869 2020. Possible treatment of Covid-19 with a therapeutic vaccine
32221001 2020. Possible method for the production of a Covid-19 vaccine
32301312 2020. Vaccins anti-covid-19 : les recherches de johnson & johnson, sanofi et pasteur
32355008 2020. COVID-19 shot protects monkeys
32300225 2020. On the front lines of the coronavirus-vaccine battle
32346146 2020. The race for coronavirus vaccines: a graphical guide
32376603 ä. Development of an inactivated vaccine candidate for SARS-CoV-2
32377399 2020. COVID-19 vaccines: breaking record times to first-in-human trials
C7152890 2020. Biomimetic nanoparticles as universal influenza vaccine

• Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus btu @OnlyTheGhosts

30993690 2019. Emerging viruses and current strategies for vaccine intervention
32259744 2020. DNA vaccines: prime time is now
32387642 2020. Innovations in structure-based antigen design and immune monitoring for next generation vaccines
32344202 2020. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development
32318055 2020. Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics Tools
16022774 2005. (+)SARS Vaccine Development
28861908 2017. (+)Issues in vaccinology: Present challenges and future directions
C7202844 ä. (+)Vaccine development during global epidemics: the Zika experience

31351923 2019. (+)First clinical trial of a MERS coronavirus DNA vaccine
16697221 2006. (+)Template-based coiled-coil antigens elicit neutralizing antibodies to the SARS-coronavirus
29852530 2020. The expanding role of mass spectrometry in the field of vaccine development
32325038 ä. (+)Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
31692019 2020. (+)Gold nanoparticle?adjuvanted S protein induces a strong antigen?specific IgG response against severe acute respiratory syndrome?related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs
32377399 2020. COVID-19 vaccines: breaking record times to first-in-human trials
32376359 2020. Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2
32418793 2020. An effective CTL peptide vaccine for Ebola Zaire Based on Survivors? CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design
32381478 2020. Enabling emergency mass vaccination: Innovations in manufacturing and administration during a pandemic
32483236 2020. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients.
32471334 2020. Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV.
32437478 2020. Harnessing the natural anti-glycan immune response to limit the transmission of enveloped viruses such as SARS-CoV-2.
32463026 2020. A Novel Vaccine Employing Non-Replicating Rabies Virus Expressing Chimeric SARS-CoV-2 Spike Protein Domains: Functional Inhibition of Viral/Nicotinic Acetylcholine Receptor Complexes.
32498742 2020. SARS-CoV-2 (COVID-19) Vaccine Development and Production: An Ethical Way Forward.

32497168 2020. On setting expectations for a SARS-CoV-2 Vaccine.
32492123 2020. The Importance of Advancing SARS-CoV-2 Vaccines in Children.

32380868 2020. Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?
32442040 2020. SARS-CoV-2, from its current highly contagious spreading toward the global development of an effective and safe vaccine: challenges and uncertainties.
32419646 2020. Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study.
32437587 2020. COVID-19 vaccines: knowing the unknown.
32460358 2020. The early landscape of COVID-19 vaccine development in the UK and rest of the world.
32441894 2020. Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events.
32427644 2020. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines: Setting Expectations Appropriately.
32203367 2020. Coronavirus vaccines: five key questions as trials begin.
32472069 2020. Questions remain following first COVID-19 vaccine results.
32273621 2020. If a coronavirus vaccine arrives, can the world make enough?

32505245 2020. COVID-19 vaccine development pipeline gears up.
32496238 2020. COVID-19 vaccine development and the way forward.
32325036 ä. (+)Two Middle East respiratory syndrome vaccines: first step for other coronavirus vaccines?
32397182 2020. (+)Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development.
32386655 2020. Influence of immune aging on vaccine responses
32497149 2020. In silico veritas? Potential limitations for SARS-CoV-2 vaccine development based on T-cell epitope prediction.